Conference Coverage

DECLARE-TIMI58 shows improved kidney function with dapagliflozin

Publish date: July 22, 2019

 

REPORTING FROM ADA 2019

Pages

Recommended Reading

The costs and benefits of SGLT2 inhibitors & GLP-1 RAs
MDedge Internal Medicine
Metformin linked to lower dementia risk in black patients
MDedge Internal Medicine
SGLT2 inhibitors, GLP-1 RAs are effective, but costly in T2D
MDedge Internal Medicine
Type 2 diabetes is particularly devastating in adolescents
MDedge Internal Medicine
Using Obamacare authority, Trump aims to shift dialysis care to patients’ homes
MDedge Internal Medicine
Low-fat dairy associated with decreased risk of type 2 diabetes
MDedge Internal Medicine
BMI screening trigger for type 2 diabetes is unreliable for at-risk black, Hispanic adults
MDedge Internal Medicine
CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes
MDedge Internal Medicine
FDA declines dapagliflozin indication as adjunct for type 1 diabetes
MDedge Internal Medicine
Plant-based foods could keep type 2 diabetes at bay
MDedge Internal Medicine